Milestone Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

Milestone Pharmaceuticals

04/08/2025 14:26

Milestone Pharmaceuticals Inc MIST.OQ MIST.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Milestone Pharmaceuticals Inc is for a loss of 18 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 64.3% above its last closing price of $1.43

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.17
-0.18
-0.31
Missed
-67.6
Dec. 31 2025
-0.14
-0.15
-0.20
Missed
-30.5
Sep. 30 2024
-0.18
-0.16
-0.14
Beat
14.3​
Jun. 30 2024
-0.19
-0.19
-0.14
Beat
26.3
​​Mar. 31 2024
-0.25
-0.26
-0.21
Beat
19.2
Dec. 31 2023
-0.30
-0.31
-0.32
Missed
-2.4​
Sep. 30 2023
-0.38
-0.38
-0.35
Beat
8.4
Jun. 30 2023
-0.38
-0.39
-0.37
Beat
4.1

This summary was machine generated August 4 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)